Clinical Trials | July 09, 2025
Novo Nordisk submits application to EMA for higher dose of Wegovy for obesity treatment
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Globally, BRUKINSA is approved in more than 70 countries
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated
